| 36.3 -0.54 (-1.47%) | 08-21 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 44.32 | 1-year : | 51.77 |
| Resists | First : | 37.95 | Second : | 44.32 |
| Pivot price | 35.85 |
|||
| Supports | First : | 34.56 | Second : | 32.47 |
| MAs | MA(5) : | 36.83 |
MA(20) : | 35.38 |
| MA(100) : | 31.65 |
MA(250) : | 25.29 |
|
| MACD | MACD : | 0.7 |
Signal : | 0.6 |
| %K %D | K(14,3) : | 79.8 |
D(3) : | 86.1 |
| RSI | RSI(14): 56.2 |
|||
| 52-week | High : | 37.95 | Low : | 11.6 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ROIV ] has closed below upper band by 39.5%. Bollinger Bands are 11.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 37.22 - 37.42 | 37.42 - 37.59 |
| Low: | 35.73 - 35.99 | 35.99 - 36.2 |
| Close: | 35.92 - 36.3 | 36.3 - 36.63 |
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.
Fri, 21 Aug 2026
Roivant (NASDAQ: ROIV) CIO sells option shares near $37 - Stock Titan
Wed, 19 Aug 2026
Roivant Sciences (ROIV) holder plans new sale after $17M June trade - Stock Titan
Wed, 19 Aug 2026
Is Roivant Sciences (ROIV) Fully Valued As First Quarter Results Show A Narrower Loss? - Sahm
Wed, 12 Aug 2026
How Roivant Sciences Ltd. (ROIV) Affects Rotational Strategy Timing - Stock Traders Daily
Mon, 10 Aug 2026
Roivant Sciences Ltd. (ROIV) Stock Analysis: Strong Buy Ratings And 15% Upside Potential - DirectorsTalk Interviews
Sat, 08 Aug 2026
Roivant Sciences: The Balance Sheet Has Become A Strategic Weapon - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 722 (M) |
| Held by Insiders | 5.7875e+008 (%) |
| Held by Institutions | 21.4 (%) |
| Shares Short | 33,240 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.36e+009 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -25 % |
| Return on Assets (ttm) | 408.1 % |
| Return on Equity (ttm) | -16.5 % |
| Qtrly Rev. Growth | 7.53e+006 % |
| Gross Profit (p.s.) | -29.65 |
| Sales Per Share | -7.54 |
| EBITDA (p.s.) | -6.40611e+008 |
| Qtrly Earnings Growth | -0.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -816 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -4.82 |
| Price to Cash Flow | 6.53 |
| Dividend | 0 |
| Forward Dividend | 3.67e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|